{
  "docId": "019de074-704c-735b-b7a3-613838aa1bf3",
  "docSlug": "9b81d8a09c69afc3f139dc970effabde",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 39 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 39,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "context",
  "function": "establish_context",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-704c-735b-b7a3-613838aa1bf3/18",
  "deckHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3",
  "deckJsonHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3.json",
  "deckAnchorHref": "/decks/019de074-704c-735b-b7a3-613838aa1bf3#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.07,
        "y": 0.0076
      },
      "kind": "callout",
      "text": "MAA Under Review with EMA, Potential Decision on Approval in Late 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03313e15-f592-49a4-bb1b-b2ddee75af66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.07,
        "y": 0.00188
      },
      "kind": "callout",
      "text": "Pegzilarginase is a novel recombinant human enzyme engineered to lower arginine levels",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6e644d7-0788-4a0a-9131-ed497a7a38b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.07,
        "y": 0.0035
      },
      "kind": "list",
      "text": "Commercial Opportunity: >2,500 patients, high unmet need, no approved therapies. Regulatory Designations: U.S. Rare Pediatric Disease, Breakthrough Therapy, U.S. Orphan Drug, EU Orphan Drug.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "45a2795d-a876-4fe8-b331-d14b9f2c7340",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.53,
        "y": 0.0035
      },
      "kind": "list",
      "text": "PEACE Phase 3 Clinical Trial: First placebo-controlled trial in ARG1-D, 76.7% arginine reduction, 90.5% normalized, positive mobility trend, well-tolerated, 31 patients in extension. Phase 1/2: 13 patients, 2-4 years, rapid/durable lowering, sustained functional improvements.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab3f7d7c-c7d4-46d5-9c07-9328d14fcb7e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.53,
        "y": 0.0021000000000000003
      },
      "kind": "paragraph",
      "text": "First Clinical Program Ever Conducted in ARG1-D",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dd176c6-1904-4189-bf8c-db895a78a685",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.1,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1 Catsburg C et al 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2893bc78-56a5-4746-9d53-e7b86c568ae7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Pegzilarginase Program Overview",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "009313eb-8117-48ef-82ab-1eb35ef9ab70",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}